TNF and inflammatory bowel disease: Women with inflammatory bowel diseases (IBD) often require biologic therapy with anti-tumor-necrosis-factor- alpha (anti-TNFα) medications during their reproductive years to control disease activity and optimize pregnancy outcomes; however, some anti-TNFα medication cross the placenta and drug level may be measurable in the infant’s blood up to 1 year (1, 2).